Back to today’s briefing

Story perspectives

HPV Testing Outshines Cytology in Cervical Risk Assessment

10/10/2025

35 4

Summary

Story summary

CIN3+ risk was 6.27% for ASC-US and 5.64% for LSIL in a China study of 1,892 Hr-HPV–positive patients with ASC-US/LSIL.
HPV status proved more significant than cytology for risk assessment.
The findings support unified follow-up for all Hr-HPV positive patients, regardless of cytology.
They align with the 2019 American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines, reinforcing Hr-HPV testing.

1 of 1

Story summary

CIN3+ risk was 6.27% for ASC-US and 5.64% for LSIL in a China study of 1,892 Hr-HPV–positive patients with ASC-US/LSIL.
HPV status proved more significant than cytology for risk assessment.
The findings support unified follow-up for all Hr-HPV positive patients, regardless of cytology.
They align with the 2019 American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines, reinforcing Hr-HPV testing.